What is AARD's current stock price?

AARD (Aardvark Therapeutics, Inc. Common Stock) is currently trading at $4.54 with a market cap of $99.0M.

What sector is Aardvark Therapeutics, Inc. Common Stock in?

Aardvark Therapeutics, Inc. Common Stock (AARD) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is AARD a good stock to buy?

Analysts have a Hold consensus on AARD with a price target of $22.75. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

AARD Aardvark Therapeutics, Inc. Common Stock

Healthcare

$4.54+0.67%ClosedMarket Cap: $99.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.14

P/S

0.00

EV/EBITDA

-0.49

DCF Value

$2.06

FCF Yield

-62.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-61.7%

ROA

-70.9%

ROIC

-85.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-21.6M	$—
Q4 null	$0.00	$-17.6M	$—
FY null	$0.00	$-57.6M	$—
Q3 null	$0.00	$-16.3M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$22.75

Target (Median)

$20.50

Target Range

$3.00 - $47.00

0 Strong Buy8 Buy4 Hold1 Sell1 Strong Sell

BTIGNeutral

2026-05-15

Morgan StanleyUnderweight

2026-05-15

B. Riley SecuritiesBuy

2026-05-15

BTIGBuy

2026-03-24

Morgan StanleyEqual Weight

2026-03-02

Trading Activity

Insider Trades

View All

Sun Nelsonofficer: Chief Financial Officer

SellWed Feb 11

Lee Tien-Lidirector, 10 percent owner, officer: Chief Executive Officer

SellWed Feb 11

Jaiman Manasiofficer: Chief Medical Officer

SellWed Feb 11

Sun Nelsonofficer: Chief Financial Officer

BuyFri Dec 12

Lee Tien-Lidirector, 10 percent owner, officer: Chief Executive Officer

BuyFri Dec 12

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

5.11

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

Peers